U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07824349) titled 'JUR-003 in Adult Patients With Metastatic Prostate Cancer' on Sept. 11.
Brief Summary: JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer. This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration Resistant Prostate Cancer
Oligometastatic Prostate...